Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer

被引:4
|
作者
Mirzaei, Roya [1 ]
Shafiee, Soodabeh [1 ]
Vafaei, Rana [1 ,3 ]
Salehi, Malihe [1 ]
Jalili, Neda [1 ]
Nazerian, Zahra [1 ]
Muhammadnajad, Ahad [2 ]
Yadegari, Fatemeh [1 ]
Esmailinejad, Mohamad Reza [3 ]
Farahmand, Leila [1 ]
机构
[1] ACECR, Motamed Canc Inst, Breast Canc Res Ctr, Recombinant Prot Dept, Tehran, Iran
[2] Univ Tehran Med Sci, Canc Inst Iran, Canc Biol Res Ctr, Tehran, Iran
[3] Univ Tehran, Fac Vet Med, Dept Surg & Radiol, Tehran, Iran
关键词
EpCAM; Antibody Fragment; Receptor Tyrosine Kinase; scFv; Breast Cancer; Recombinant; MONOCLONAL-ANTIBODIES; CARCINOMA-CELLS; MIGRATION; FRAGMENT; ADHESION; PREDICTION; DIAGNOSIS; INVASION;
D O I
10.1016/j.intimp.2023.110656
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The utilization of monoclonal antibodies (moAbs), an issue correlated with the biopharmaceutical professions, is developing and maturing. Coordinated with this conception, we produced the appealingly modeled anti-EpCAM scFv for breast cancer tumors.Methods: Afterward cloning and expression of recombinant antibody in Escherichia coli bacteria, the correctness of the desired antibody was checked by western blotting. Flow cytometry was utilized to determine the capacity of the recombinant antibody to append to the desired receptors in the malignant breast cancer (BC)cell line. The recombinant antibody (anti-EpCAM scFv) was examined for preclinical efficacy in reducing tumor growth, angiogenesis, and invasiveness (in vitro-in vivo).Findings: A target antibody-mediated attenuation of migration and invasion in the examined cancer cell lines was substantiated (P-value < 0.05). Grafted tumors from breast cancer in mice indicated significant and compelling suppression of tumor growth and decrement in blood supply in reaction to the recombinant anti-EpCAM intervention. Evaluations of immunohistochemical and histopathological findings revealed an enhanced response rate to the treatment.Conclusion: The desired anti-EpCAM scFv can be a therapeutic tool to reduce invasion and proliferation in ma-lignant breast cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-EpCam x Anti-CD3) for Epithelial Ovarian Cancer
    Papanikolaou, Georgios
    Fotopoulou, Christina
    Braicu, Ioana
    Chekerov, Radoslav
    Schmidt, Sven Christian
    Pietzner, Klaus
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2011, 31 (08) : 2603 - 2608
  • [42] The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer.
    Reinhard, H.
    Meyer, S. K.
    Bartels, K.
    Fischer, R.
    Seimetz, D.
    Bokemeyer, C.
    Atanackovic, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] FIRST RESULTS FROM A PHASE 1B STUDY OF THE ANTI-EPCAM ANTIBODY ADECATUMUMAB (MT201) IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER
    Schuler, M.
    Hanusch, C.
    Steger, G. G.
    Schmidt, M.
    Lang, A.
    Wolf, C.
    Sebastian, M.
    Schmidt, M.
    Reinhardt, C.
    Eiermann, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 161
  • [44] Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of Anti-Epcam and Anti-VEGFR2 Nanobodies
    Karami, Elmira
    Azizi, Parisa
    Behdani, Mahdi
    Kazemi-Lomedasht, Fatemeh
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (13) : 1059 - 1066
  • [45] Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody
    Andratschke, Michaela
    Gildehaus, Franz Josef
    Johannson, Veronika
    Schmitt, Baerbel
    Mack, Brigitte
    Reisbach, Gilbert
    Lang, Stephan
    Lindhofer, Horst
    Zeidler, Reinhard
    Wollenberg, Barbara
    Luebbers, Christian W.
    ANTICANCER RESEARCH, 2007, 27 (1A) : 431 - 436
  • [46] Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer
    Connor, JP
    Felder, M
    Hank, J
    Harter, J
    Gan, J
    Gillies, SD
    Sondel, P
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (03) : 211 - 219
  • [47] Chimeric Recombinant Anti-CD24 Antibody: A Novel Tool for Colorectal Cancer Therapy
    Shapira, Shiran
    Kraus, Sarah
    Kazanov, Diana
    Stahel, Rolf
    Benhar, Itay
    Arber, Nadir
    GASTROENTEROLOGY, 2010, 138 (05) : S499 - S499
  • [48] Trastuzumab - a monoclonal antibody - and dendrimers in a targeted therapy for breast cancer
    Marcinkowska, Monika
    Stanczyk, Maciej
    Klajnert-Maculewicz, Barbara
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2015, 69 : 1313 - 1324
  • [49] Development of recombinant MUC1-single chain antibody for in vivo imaging and targeted therapy in breast cancer
    Bandyopadhyay, D
    Hyland, S
    Singh, R
    Wels, W
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 88 - 88
  • [50] Anti-uPAR antibody drug conjugates for targeted therapy of triple-negative breast cancer
    Harel, Efrat
    McFarland, Jesse
    Bleck, Gregory
    Brain, Susie
    Drake, Penelope
    Rabuka, David
    Vantveer, Laura
    Craik, Charles
    CANCER RESEARCH, 2018, 78 (04)